Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Editas Medicine, Inc. - Common Stock
(NQ:
EDIT
)
2.455
+0.090 (+3.81%)
Streaming Delayed Price
Updated: 10:21 AM EST, Dec 4, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Editas Medicine, Inc. - Common Stock
< Previous
1
2
3
Next >
Editas Medicine Announces Third Quarter 2025 Results and Business Updates
November 10, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
November 03, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
October 09, 2025
Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse models
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
October 06, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
September 02, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
August 28, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Participate in Upcoming Investor Conferences
August 27, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Second Quarter 2025 Results and Business Updates
August 12, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
June 12, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
May 14, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting
May 14, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting
May 13, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces First Quarter 2025 Results and Business Updates
May 12, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board
May 12, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May
May 05, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
April 28, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Chief Financial Officer Transition
March 20, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates
March 05, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March
February 24, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities
January 13, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
December 12, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
December 09, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Participate in Upcoming Investor Conferences
November 06, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Third Quarter 2024 Results and Business Updates
November 04, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
October 22, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
October 21, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
October 18, 2024
Webinar to be held on Tuesday, October 22, at 8:00 a.m. ET
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
October 03, 2024
Strengthens balance sheet with non-dilutive capital to enable further pipeline development and related strategic priorities
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Participate in Upcoming Investor Conferences
August 28, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
